^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    1d
    CATALYST: Choices About Genetic Testing And Learning Your Risk With Smart Technology (clinicaltrials.gov)
    P=N/A, N=50, Completed, Rutgers, The State University of New Jersey | Active, not recruiting --> Completed
    Trial completion
    4d
    Weakly supervised deep learning-based detection of serous tubal intraepithelial carcinoma in fallopian tubes. (PubMed, J Pathol Inform)
    Interpretability analyses indicated that model decisions were based on epithelial atypia. These results support the potential of integrating deep learning screening tools into clinical workflows to augment pathologist efficiency and diagnostic accuracy in fallopian tubes.
    Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    4d
    A Case of Uterine Serous Carcinoma in a Patient with a Germline BRCA1 Mutation: Genomic Profiling Reveals an Ovarian Cancer-Like Molecular Signature. (PubMed, Case Rep Oncol)
    This finding suggests that BRCA1-associated USC may be sensitive to poly ADP-ribose polymerase inhibitors, and also raises the question of whether risk-reducing hysterectomy should be considered for patients with BRCA1 mutation. USC with a BRCA1 mutation may have molecular characteristics distinct from those of sporadic USC, and further accumulation and analysis of such cases are needed to evaluate the clinical implications.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • RB1 (RB Transcriptional Corepressor 1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1)
    |
    TP53 mutation • PIK3CA mutation
    14d
    Assessment of Active Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Infections and Patient Reported Fatigue in Ovarian Cancer Survivors. (PubMed, Cancer Rep (Hoboken))
    We did not observe associations between CMV DNAemia, EBV DNAemia, or hsCRP and fatigue in this survivor population. Further investigation is needed to identify causes and indicators of cancer-related fatigue following treatment for ovarian cancer.
    Journal
    |
    CRP (C-reactive protein)
    15d
    Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer (clinicaltrials.gov)
    P=N/A, N=94, Recruiting, Shanghai Gynecologic Oncology Group | Not yet recruiting --> Recruiting | Phase classification: P2 --> PN/A | N=69 --> 94
    Enrollment open • Phase classification • Enrollment change
    16d
    MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Sep 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    20d
    REPURPOSE: Phase II study of Efavirenz in platinum resistant or heavily pretreated high-grade serous ovarian cancer (ACTRN12625001259437)
    P2, N=48, Not yet recruiting, The University of Newcastle
    New P2 trial • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    21d
    Preferences of BRCA mutation carriers for attributes of risk-reducing surgical options for breast and ovarian cancer. (PubMed, Cancer)
    These findings demonstrate the heterogeneity of preferences and support individualized discussion of treatment goals relating to risk-reducing surgical planning.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA mutation
    21d
    TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    Avastin (bevacizumab) • sapanisertib (CB-228) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    22d
    Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=33, Recruiting, Masonic Cancer Center, University of Minnesota | Suspended --> Recruiting
    Enrollment open
    |
    fludarabine IV
    22d
    FRAmework-01: A Two-Part Phase 3 Study of LY4170156 in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (clinicaltrials.gov)
    P3, N=1080, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open • Platinum sensitive • Platinum resistant
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • LY4170156
    24d
    Heterogeneity and Scoring Reproducibility of Folate Receptor 1 Immunohistochemistry in High-grade Serous Carcinoma. (PubMed, Int J Gynecol Pathol)
    Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate approved for the treatment of adult patients with folate receptor 1 (FRα; FOLR1) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens...Our study highlights several factors contributing to heterogeneity in FOLR1 reporting. Future studies are needed to better understand the impact of FOLR1 heterogeneity on patient response to therapy.
    Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 positive
    |
    VENTANA FOLR1 RxDx Assay
    |
    Elahere (mirvetuximab soravtansine-gynx)